Pharmacokinetics/pharmacodynamics of benralizumab in chronic rhinosinusitis with nasal polyps: Phase III, randomized, placebo‐controlled OSTRO trial
British Journal of Clinical Pharmacology · 2024
DOI: 10.1111/bcp.16087 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift British Journal of Clinical Pharmacology, 2024. Verfasst von Claire Emson und 14 weiteren Autor:innen. Beteiligte Einrichtung: AstraZeneca, Gaithersburg, Maryland, USA. Hauptthemen laut MEDLINE: Nasal Polyps, Antibodies, Monoclonal, Humanized, Sinusitis, Rhinitis. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AstraZeneca.
Abstract (Originalsprache)
Aims
Benralizumab, a humanized, afucosylated monoclonal antibody against the interleukin 5 receptor, α subunit, causes rapid depletion of eosinophils by antibody‐dependent cellular cytotoxicity. We investigated the pharmacokinetic and pharmacodynamic effects of benralizumab in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) from the phase III OSTRO trial.
Methods
Patients received a placebo or 30 mg of benralizumab by subcutaneous injection every 8 weeks (first three doses every 4 weeks) to week 48; a subset of patients continued in an extended follow‐up period to assess treatment durability to week 80. Serum benralizumab concentrations and blood eosinophil and basophil counts were assessed to week 80. Biomarker assessments were performed on nasal polyp tissue biopsies at week 56 and nasal lining fluid at weeks 24 and 56 to examine changes in immune cells and inflammatory mediators.
Results
Among 185 patients in this analysis, 93 received benralizumab. Serum benralizumab concentrations reached a steady state by week 24 (median concentration 385.52 ng mL −1 ); blood eosinophils were almost fully depleted and blood basophils were reduced between weeks 16 and 56. Nasal polyp tissue eosinophils decreased with benralizumab from 57.6 cells mm −2 at baseline to 0 cells mm −2 at week 56 ( P < .001 vs placebo), and tissue mast cells were numerically reduced. In nasal lining fluid, eosinophil‐derived neurotoxin was significantly reduced at weeks 24 and 56 ( P < .001) and interleukin‐17 at week 56 ( P < .05) with benralizumab.
Conclusion
Benralizumab treatment led to rapid, sustained, nearly complete depletion of eosinophils from blood and nasal polyp tissue in patients with CRSwNP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- AstraZeneca, Gaithersburg, Maryland, USA.
- Eastern Virginia Medical School, Norfolk, Virginia, USA.
- Guy's and St. Thomas' NHS Trust, London, UK.
- AstraZeneca, Gothenburg, Sweden.
- Department of Medical Affairs, Vertex Pharmaceuticals, Boston, Massachusetts, USA.
- Department of Otorhinolaryngology, University Hospital Düsseldorf, Düsseldorf, Germany.
ORCID-Profile: Sara Asimus
Förderung
- AstraZeneca
Zitieren
APA
Emson, C., Han, J. K., Hopkins, C., Asimus, S., Cann, J. A., Chain, D., Wu, Y., Reddy, Y., McCrae, C., Cohen, D., Kreindler, J. L., Werkström, V., Jison, M., Wagenmann, M., & Bachert, C. (2024). Pharmacokinetics/pharmacodynamics of benralizumab in chronic rhinosinusitis with nasal polyps: Phase III, randomized, placebo‐controlled OSTRO trial. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16087
Vancouver
Emson C, Han JK, Hopkins C, Asimus S, Cann JA, Chain D, et al. Pharmacokinetics/pharmacodynamics of benralizumab in chronic rhinosinusitis with nasal polyps: Phase III, randomized, placebo‐controlled OSTRO trial. British Journal of Clinical Pharmacology. 2024. doi:10.1111/bcp.16087
BibTeX
@article{Emson2024,
author = {Emson, Claire and Han, Joseph K and Hopkins, Claire and Asimus, Sara and Cann, Jennifer A and Chain, David and Wu, Yuling and Reddy, Yasa and McCrae, Christopher and Cohen, David and Kreindler, James L and Werkström, Viktoria and Jison, Maria and Wagenmann, Martin and Bachert, Claus},
title = {Pharmacokinetics/pharmacodynamics of benralizumab in chronic rhinosinusitis with nasal polyps: Phase III, randomized, placebo‐controlled OSTRO trial},
journal = {British Journal of Clinical Pharmacology},
year = {2024},
doi = {10.1111/bcp.16087}
}
EUVIMED